Stock research
Quest Diagnostics Incorporated DGX
Delayed Cboe One market data via TradingView. It may differ from primary-exchange or consolidated quotes.
- Ticker
- DGX
- Exchange
- NYSE
- Sector
- Health
- Founded
- —
What moves DGX
Quest Diagnostics Incorporated sits in Health Care. Pharmaceuticals, biotech, medical devices, and managed care — defensive demand paired with binary drug and regulatory catalysts. The forces that matter most for the sector — and therefore for DGX — are:
- ◆Drug approvals and clinical-trial readouts
- ◆Medicare and drug-pricing policy
- ◆Demographics and an aging population
- ◆GLP-1 and obesity-drug demand
Congressional trading in DGX
No matched DGX transaction appears in the current verified House Clerk snapshot. We do not turn a missing row into a claim that no member has ever traded the security.
Congressional disclosures are delayed, range-based records—not real-time signals or proof of motive. See the source-linked tracker for scope and limitations.
The profile is free
DGX research stays free. Membership is the living thesis: what we believe, what we’re watching, and when conviction should end.
Profiles related to Health Care
How Yield Theory covers DGX
DGX intersects several of the themes in every Yield Theory issue. We don't chase headlines on individual tickers — we track where capital is rotating and explain what it means for the names in its path.
Compare DGX with similar companies
More Health Care stocks
DGX — frequently asked questions
What sector is DGX in?
Quest Diagnostics Incorporated is classified in the Health Care sector and trades on the NYSE.
Do members of Congress trade DGX?
The current verified House Clerk snapshot contains no matched DGX transaction rows. That is not proof that no lawmaker has ever traded the security.
Is DGX a good investment?
We don't publish one-line buy/sell ratings. Yield Theory members get the full macro thesis, catalysts, and risks behind every name we cover, so you can decide with conviction. This page is research, not investment advice.
This page is independent research and educational information, not investment advice or a recommendation to buy or sell any security. Company facts are compiled from public sources. Do your own research.
See whether the DGX thesis still holds.
This page is company context and filings. Members get one sourced monthly call, a weekly evidence check, and the breakpoint written in advance. $15/month or $150/year.
$15/mo or $150/yr · cancel future renewals anytime · sources included